Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
J&J, Legend Report Carvykti Cut Death Risk by 45% in Multiple Myeloma Study
J&J Releases Encouraging Data on Talvey Combination Therapies
Johnson & Johnson's CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After...
Merck Snaps Six Straight Sessions of Losses
loading...
MonkeyGee OP :